SCYNEXIS, Inc. (SCYX) — 分析摘要
SCYNEXIS, Inc.（SCYX）的市值为40.10百万美元，最近一年的营收同比增长了+449.9%。净利润率为-41.8%。当前市盈率为-3.9倍。
核心要点
- 营收同比变化+449.9%
- 净利润率-41.8%
- 市盈率-3.9倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，SCYX的营收增长为+449.9%，市盈率为-3.9倍。
SCYNEXIS, Inc. (SCYX)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -117.6% — 严重经营亏损
净利率为 -53.3% — 亏损显著
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
29
总部
JERSEY CITY, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。